In contrast to breast cancer and although few patients harbor both a HER2 amplification and mutation, HER2 mutations in most cases are not associated with amplification or overexpression, suggesting a distinct entity and, thus, different therapeutic targets [46]. This evidence concerns the gene ERBB2 and breast carcinoma.